Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Anisha Misra, Elitza S. Theel
Abstract
hybrid immunity), as well as adaptive cellular immune responses, serve as CoPs for COVID-19. However, the diverse number and type of serologic assays, alongside the lack of cross-assay standardization and emergence of new SARS-CoV-2 variants with immune evasive characteristics, have collectively posed challenges to determining a robust CoP 'threshold' and for the routine utilization of these assays to document 'immunity,' as is commonly done for other vaccine preventable diseases. Here, we discuss what CoPs are, review our current understanding of infection-induced, vaccine-elicited and hybrid immunity to COVID-19 and summarize the current and potential future utility of SARS-CoV-2 serologic testing.
Topics & Concepts
ImmunityPandemicVaccinationImmunologyVirologyHerd immunityTransmission (telecommunications)Acquired immune systemImmune systemSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)SerologyCoronavirusBiologyMedicineCoronavirus disease 2019 (COVID-19)Infectious disease (medical specialty)AntibodyDiseaseElectrical engineeringPathologyEngineeringSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing